R., Kalantar M
DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) revealed that the use of dapagliflozin in patients with New York Heart Association (NYHA) class II, III, or IV heart failure and an ejection fraction of 40% resulted in a lower risk of worsening heart failure and cardiovascular death
The concern from geriatric specialists is that the absence of a mandate means many older patients will begin therapy without these protections in place
Other Ingredients: Microcrystalline Cellulose, Hydroxypropyl Cellulose, Magnesium Stearate, Maltodextrin, Talc, Guar Gum, Hydroxypropyl Methylcellulose, Polyvinyl Alcohol, Silica, Medium Chain Triglycerides
[DOI] [PubMed] [Google Scholar] 95.Baumgartner T., Heinrichs M., Vonlanthen A., Fischbacher U., Fehr E